Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Acute and Chronic Lymphoblastic Leukemia
  • Track 1-2Hodgkins and Non-Hodgkins Lymphoma
  • Track 1-3Myelodysplastic Syndromes
  • Track 1-4Multiple Myeloma
  • Track 1-5Myeloma Cancer
  • Track 1-6Myeloid Leukemia
  • Track 2-1Umbilical Cord Blood Transplantation
  • Track 2-2Bone Marrow Transplantation
  • Track 2-3Autologous Transplantation
  • Track 2-4Thromboembolism
  • Track 2-5Hemostasis
  • Track 2-6Metabolic Syndrome
  • Track 3-1Molecular Pathogenesis
  • Track 3-2Genetic Blood Disorders
  • Track 3-3Hemophilia A, B and C
  • Track 3-4Idiopathic Thrombocytopenic Purpura (ITP)
  • Track 3-5Von Willebrand
  • Track 3-6Bleeding Disorders
  • Track 3-7Coagulation Factors
  • Track 3-8Hemoglobinopathies
  • Track 3-9Biomarkers for Blood Cancers
  • Track 4-1Diagnostics
  • Track 4-2Splenectomy
  • Track 5-1Hematology Research
  • Track 5-2Blood Components
  • Track 5-3Erythrocytes and Leukocytes
  • Track 5-4Platelets and Thrombocytopenia
  • Track 5-5Hemoglobin and Blood Plasma
  • Track 5-6Complete Blood Count and Polycythemia
  • Track 5-7Different Types of Anemia
  • Track 5-8Polymorphism and Hematopoiesis
  • Track 6-1Hematology and Oncology
  • Track 6-2Pediatric Haematology
  • Track 6-3Hematopathology
  • Track 6-4Experimental Hematology
  • Track 6-5Scope of Animal Haematology
  • Track 6-6Hematology practice
  • Track 6-7Contribution of Blood Banks
  • Track 6-8Future prospects of Hematology Research
  • Track 6-9Clinical Hematology
  • Track 7-1Hematologiest meeting
  • Track 7-2Pathogen Reduction Technologies
  • Track 7-3Latest Treatment Strategies and Technologies
  • Track 7-4Artificial blood
  • Track 7-5Bio-Engineered Red Blood Cell Production
  • Track 7-6Therapeutic Biological Product
  • Track 7-7Oral Anticoagulants
  • Track 9-1Biological Drugs
  • Track 9-2Generic Drugs
  • Track 9-3Increasing Investments
  • Track 9-4Healthcare Expenditures
  • Track 9-5Cancer Pharmaceutical Companies
  • Track 10-1Anemias
  • Track 10-2Blood cancers
  • Track 10-3Coagulation, purpura, and other hemorrhagic conditions
  • Track 10-4Immune system regulation-related
  • Track 11-1Hematology Blood test
  • Track 11-2Hematology pathophysiology
  • Track 12-1Gene therapy
  • Track 12-2Vena Cava Filters
  • Track 12-3Surgery, Chemotherapy and Radiotherapy
  • Track 12-4Targeted therapy
  • Track 12-5Role of Translational Medicine
  • Track 13-1B and T-Lymphocyte
  • Track 13-2Clinical Immunology
  • Track 13-3Immunology of Blood Cancer
  • Track 13-4Autoimmune Diseases
  • Track 13-5Stem Cell Transplantation Strategies